Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Bioenvision was incorporated as Express Finance Inc on 16th August 1996 and changed its name to Ascott Group Inc
in August 1998 and further to Bioenvision Inc in December 1998, at which time the company merged with Bioenvision
Inc (Old Bioenvision) a development-stage company primarily engaged in the research and development of products
and technologies for the treatment of cancer.
Bioenvision is an emerging biopharmaceutical company primarily engaged in the development and distribution of
drugs to treat cancer. The company is currently developing a number of products for a wide range of cancers including
breast, prostate, colorectal, pancreatic, bladder, acute myeloid leukaemia, acute lymphocytic leukaemia, chronic
lymphocytic leukaemia and lymphoma. In addition, it is planning to develop products for other diseases and is actively
pursuing the animal health market.